Cost-Effectiveness of Ruxolitinib for The Treatment of Myelofibrosis In Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2446
https://www.valueinhealthjournal.com/article/S1098-3015(15)04522-2/fulltext
Title :
Cost-Effectiveness of Ruxolitinib for The Treatment of Myelofibrosis In Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04522-2&doi=10.1016/j.jval.2015.09.2446
First page :
A669
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1854